Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001219284 | SCV001391216 | benign | Tuberous sclerosis 2 | 2023-10-04 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002504273 | SCV002815760 | uncertain significance | Lymphangiomyomatosis; Isolated focal cortical dysplasia type II; Tuberous sclerosis 2 | 2022-02-16 | criteria provided, single submitter | clinical testing | |
Laboratory of Molecular Epidemiology of Birth Defects, |
RCV003153948 | SCV003843565 | likely pathogenic | Ovarian cancer | 2022-01-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003163686 | SCV003862800 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-11-17 | criteria provided, single submitter | clinical testing | The p.T1572M variant (also known as c.4715C>T), located in coding exon 36 of the TSC2 gene, results from a C to T substitution at nucleotide position 4715. The threonine at codon 1572 is replaced by methionine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
All of Us Research Program, |
RCV004010725 | SCV004818082 | uncertain significance | Tuberous sclerosis syndrome | 2023-07-07 | criteria provided, single submitter | clinical testing |